Chemotherapy agents are used as an effective disease-modifying treatment for Multiple Sclerosis.
the verdict
SUPPORTED
the evidence backs this
confidence 85/100
Chemotherapy-based conditioning regimens used in procedures like autologous hematopoietic stem cell transplantation and potent immunosuppressive disease-modifying treatments serve as effective strategies to manage and alter the disease course in multiple sclerosis.
Evidence for · 6
Immune Reconstitution Following Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis: A Review on Behalf of the EBMT Autoimmune Diseases Working Party.
2021 · cited by 37
Autologous hematopoietic stem cell transplantation uses intensive chemotherapy regimens to eradicate autoreactive immune cells and induce long-term remission in multiple sclerosis.
See more details
More for · 5
The Role of Chimeric Antigen Receptor T-Cell Therapy in Immune-Mediated Neurological Diseases.
2024 · cited by 13
Intense chemotherapy-based approaches such as autologous hematopoietic stem cell transplantation serve as effective treatments for immune-mediated neurological diseases.
BEAM or cyclophosphamide in autologous haematopoietic stem cell transplantation for relapsing-remitting multiple sclerosis.
2024 · cited by 8
Chemotherapy conditioning regimens like BEAM and cyclophosphamide are utilized in autologous hematopoietic stem cell transplantation for relapsing-remitting multiple sclerosis.
Cellular Immunotherapies for Multiple Sclerosis: Mechanistic Insights and Clinical Advances.
2026 · cited by 1
Cellular immunotherapies and targeted treatments involving potent immunosuppressive and lympho-ablative agents modify the immunopathogenesis of multiple sclerosis.
Rituximab for people with multiple sclerosis.
2025 · cited by 1
Rituximab and other off-label disease-modifying therapies effectively reduce relapses in multiple sclerosis.
Disease-Modifying Therapy (DMT) Switch in Highly Active Multiple Sclerosis: A Case Report
2025 · cited by 0
Immune-reconstitution disease-modifying therapies, including potent medications like cladribine, help achieve no evidence of disease activity in highly active multiple sclerosis.